Glimp M1 SR Tablet is a combination oral hypoglycemic agent containing Glimepiride 1mg and Metformin 500mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The sustained-release (SR) formulation ensures a gradual release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Glimp M1 SR is indicated as an adjunct to diet and exercise to improve glycemic control in patients inadequately controlled on metformin or sulfonylurea monotherapy or those already on combination therapy. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerance. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. Glimp M1 SR Tablet should be used under medical supervision, with lifestyle modifications to optimize diabetes management and reduce the risk of complications.